Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD

By sjmartinez • February 13, 2025

Sciurba FC, Christenson SA, Rheault T, Bengtsson T, Rickard K, Barjaktarevic IZ. Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD. Chest. 2025 Feb;167(2):425-435. doi: 10.1016/j.chest.2024.07.168. Epub 2024 Aug 27. PMID: 39197510.

Tags: COPD, ensifentrine, exacerbation, patient-reported outcomes, Publications, Pulmonary, Critical Care & Sleep Medicine

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA,[...]

Artificial intelligence and computer-aided diagnosis in diagnostic decisions: 5 questions for medical informatics and human-computer interface research

Brunyé TT, Mitroff SR, Elmore JG. Artificial intelligence and computer-aided diagnosis in diagnostic decisions: 5 questions for medical informatics and human-computer interface research. J Am[...]

FAP Expression in Renal Tumors Assessed by [68Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients from the Prospective Exploratory Trial NCT04147494

Holzgreve A, Unterrainer LM, Flores K, Lam EC, Mona CE, Czernin J, Shuch BM, Sisk AE Jr, Calais J. FAP Expression in Renal Tumors Assessed[...]